List of Excipients in Branded Drug HEPARIN SODIUM IN SODIUM CHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	HEPARIN SODIUM IN SODIUM CHLORIDE	heparin sodium in sodium chloride	0264-3301	ANHYDROUS CITRIC ACID
B Braun Medical Inc	HEPARIN SODIUM IN SODIUM CHLORIDE	heparin sodium in sodium chloride	0264-3301	SODIUM CHLORIDE
B Braun Medical Inc	HEPARIN SODIUM IN SODIUM CHLORIDE	heparin sodium in sodium chloride	0264-3301	SODIUM PHOSPHATE, DIBASIC
B Braun Medical Inc	HEPARIN SODIUM IN SODIUM CHLORIDE	heparin sodium in sodium chloride	0264-3301	WATER
B Braun Medical Inc	HEPARIN SODIUM IN SODIUM CHLORIDE	heparin sodium in sodium chloride	0264-9872	ANHYDROUS CITRIC ACID
B Braun Medical Inc	HEPARIN SODIUM IN SODIUM CHLORIDE	heparin sodium in sodium chloride	0264-9872	SODIUM CHLORIDE
B Braun Medical Inc	HEPARIN SODIUM IN SODIUM CHLORIDE	heparin sodium in sodium chloride	0264-9872	SODIUM PHOSPHATE, DIBASIC

Heparin Sodium in Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Heparin sodium in sodium chloride is a mature injectable product with limited conventional patent protection and strong demand in hospitals, intensive-care units, cardiac procedures, dialysis, and extracorporeal circuits. The commercial opportunity is concentrated in manufacturing reliability, ready-to-administer presentation, concentration selection, container performance, shortage resilience, and procurement economics rather than novel excipient ownership.

The most defensible product strategy is a preservative-free, ready-to-use intravenous premix using sodium chloride injection as the vehicle, with validated stability, low extractables and leachables, robust container closure performance, and concentrations aligned with hospital protocols.

What is heparin sodium in sodium chloride used for?

Heparin sodium in sodium chloride is an intravenous anticoagulant solution used when continuous systemic anticoagulation is required. Common clinical applications include:

• Prevention and treatment of venous and arterial thrombosis
• Acute coronary syndromes and interventional cardiology
• Cardiopulmonary bypass and extracorporeal circuits
• Hemodialysis
• Intensive-care anticoagulation
• Selected vascular and surgical procedures

The product is distinct from low-molecular-weight heparins such as enoxaparin. It contains unfractionated heparin, a heterogeneous mixture of sulfated polysaccharide chains derived commercially from animal tissue, primarily porcine intestinal mucosa.

Typical premix presentations use sodium chloride injection as the diluent and are supplied in flexible intravenous bags. Labeling commonly identifies the heparin concentration in units per milliliter rather than only by mass.

Representative product configurations

Heparin content	Sodium chloride volume	Nominal concentration	Commercial use
25,000 units	250 mL	100 units/mL	Continuous hospital infusion
50,000 units	500 mL	100 units/mL	Continuous infusion, larger-volume administration
25,000 units	500 mL	50 units/mL	Lower-concentration infusion protocols
Custom pharmacy preparation	Variable	Variable	Institution-specific dosing

The appropriate concentration depends on hospital protocols, infusion-pump settings, patient population, and the risk of medication errors. Ready-to-use premixes reduce compounding steps and can reduce preparation burden in high-volume hospital settings.

What excipients are used in heparin sodium in sodium chloride?

The core formulation is simple. The principal excipients are sodium chloride and water for injection. Hydrochloric acid or sodium hydroxide may be used for pH adjustment, depending on the product and manufacturing process.

Component	Function	Strategic importance
Heparin sodium	Active anticoagulant	Potency, impurity profile, source control and biological consistency
Sodium chloride	Isotonic vehicle	Osmolality, infusion compatibility and dose-volume control
Water for injection	Solvent	Microbiological and chemical quality
Hydrochloric acid or sodium hydroxide	pH adjustment	Stability and product consistency
Container-closure system	Not an excipient, but formulation-critical	Adsorption, leachables, oxygen exposure and usability

Most commercial intravenous premixes are preservative-free. A preservative generally offers limited value in a single-use intravenous bag and can introduce toxicity, compatibility, or regulatory complexity.

Why sodium chloride is the preferred vehicle

Sodium chloride injection is familiar to hospitals, compatible with common intravenous administration practices, and commercially available in multiple bag volumes. It also avoids the operational complexity of a separate dilution step.

The formulation target is not simply chemical stability. The product must maintain:

• Heparin potency over labeled shelf life
• Acceptable pH and osmolality
• Low particulate burden
• Sterility and container-closure integrity
• Consistent delivery through the administration set
• Low adsorption to the container and tubing system
• Low risk of visible or subvisible contamination

What formulation patents protect heparin sodium in sodium chloride?

Standard heparin sodium in sodium chloride has a weak patent moat. Heparin sodium and sodium chloride injection are long-established products, and the basic combination is unlikely to support meaningful new-product exclusivity by itself.

The relevant protection categories are:

1. Composition patents covering a new heparin formulation
2. Container or delivery-system patents
3. Manufacturing process patents
4. Stability-enhancing formulation patents
5. Device or infusion-system claims
6. Method-of-use patents for a narrowly defined clinical indication

For a conventional preservative-free premix, the practical barriers are more likely to be regulatory, manufacturing, supply-chain, and quality-related than patent-related.

Are there Paragraph IV challenges for heparin sodium in sodium chloride?

Paragraph IV litigation is generally not the primary market-access issue for a mature heparin sodium premix. A Paragraph IV certification is relevant when an ANDA applicant challenges a listed patent associated with a reference drug. For a standard heparin sodium injection product with no commercially meaningful blocking patent, market entry is more likely to depend on ANDA approval, manufacturing capacity, bioequivalence or pharmaceutical-equivalence requirements, and institutional contracting.

Potential applicants should review the current FDA Orange Book and approved drug-label database for the selected reference product before filing. A product-specific patent position can differ by manufacturer, presentation, and dosage strength. FDA’s Orange Book remains the controlling source for listed patents and exclusivity information. [1]

What is the FDA regulatory status of heparin sodium in sodium chloride?

Heparin sodium in sodium chloride is an FDA-approved prescription injectable drug product. The product is regulated as a drug rather than as a biosimilar under the Biologics Price Competition and Innovation Act pathway.

A conventional generic development program may use an abbreviated application pathway when the proposed product can meet applicable sameness, quality, strength, route, dosage-form, and labeling requirements. Heparin is a complex biological mixture, so source material, potency assignment, impurity control, and analytical comparability receive close scrutiny.

Does heparin sodium qualify for a biosimilar pathway?

No. Heparin sodium injection is not normally developed as a biosimilar to a therapeutic protein. It is a complex carbohydrate mixture and is generally pursued through a drug approval pathway, commonly an ANDA where the product fits the reference-product framework.

The key technical burden is not biosimilar clinical comparability. It is control of:

• Heparin identity and potency
• Molecular-weight distribution
• Degree and pattern of sulfation
• Residual proteins and nucleic acids
• Endotoxin
• Microbial contamination
• Over-sulfated or process-related impurities
• Animal-origin supply-chain controls

FDA’s historical heparin safety actions show the importance of impurity surveillance and supply-chain traceability. [2]

How strong is the patent estate for heparin sodium in sodium chloride?

The patent estate is weak for the basic drug product and potentially stronger for differentiated delivery systems or manufacturing technologies.

Protection area	Expected strength for a conventional premix	Commercial relevance
Heparin sodium active ingredient	Low	Mature active ingredient
Sodium chloride vehicle	None	Established excipient
Basic heparin-in-saline composition	Low	Limited novelty
Concentration and bag volume	Low to moderate	May support product differentiation, not usually a strong moat
Container system	Moderate	Can protect usability, adsorption control or packaging performance
Manufacturing process	Moderate	May protect yield, impurity control or source conversion
Stability package	Moderate	Useful if tied to defined materials and conditions
Infusion device integration	Moderate to strong	Potentially valuable when combined with a proprietary device
Method of use	Low to moderate	Narrow clinical claims may have limited commercial effect

Patent value increases when a formulation solves a documented technical problem, such as heparin loss through adsorption, instability during extended storage, incompatibility with a particular container, or improved dosing safety. A claim directed only to mixing a known amount of heparin with normal saline is unlikely to provide durable differentiation.

What excipient strategy offers the best commercial opportunity?

The strongest strategy is controlled simplicity rather than excipient complexity.

1. Use a preservative-free formulation

A preservative-free product is well aligned with intravenous hospital use. It avoids concerns associated with benzyl alcohol and other antimicrobial preservatives and supports single-use packaging.

2. Optimize concentration around clinical workflow

A manufacturer can target concentrations that reduce bedside dilution and minimize pump programming errors. The primary opportunity is not creating an unusual concentration, but aligning available strengths with common protocols.

Potential offerings include:

• 50 units/mL for lower-dose continuous infusions
• 100 units/mL for standard adult infusion protocols
• Higher-concentration formats for selected specialist applications, subject to regulatory and medication-safety review

Concentration differentiation should be supported by clear labeling, color coding where permitted, barcode identification, and separation from flush products.

3. Select the container around adsorption and extractables performance

The container is part of the product’s quality strategy. Development should compare:

• PVC bags
• Non-PVC multilayer bags
• Polyolefin containers
• Glass bottles where appropriate
• Administration sets and tubing used with the product

The study program should measure heparin recovery over shelf life, after simulated shipping, and during administration through representative tubing systems. Extractables and leachables testing should address the complete product-contact system, not only the primary container.

4. Design for hospital inventory efficiency

A ready-to-administer bag can reduce pharmacy compounding time, eliminate some dilution steps, and improve availability during staffing shortages. Commercial value increases when the product can be stored and issued through standard hospital inventory systems without special handling.

5. Build a low-waste presentation

Hospitals may value:

• Unit-dose bags
• Multiple fill volumes
• Clear overwrap labeling
• Barcoded secondary packaging
• Compact case configurations
• Shelf-life targets that reduce inventory write-offs

The product must balance low fill volume against the requirements of continuous infusion and pump programming.

What manufacturing and intellectual-property barriers affect market entry?

The most important barriers are operational.

Heparin raw-material sourcing

Heparin is derived from animal tissue. A commercial supplier must control:

• Approved source countries and slaughterhouses
• Species and tissue documentation
• Traceability to raw material
• Viral and microbial controls
• Residual impurities
• Batch-to-batch potency
• Supply concentration among qualified suppliers

Raw-material supply is a greater strategic risk than sodium chloride availability.

Analytical control

A strong control strategy should include orthogonal methods for identity, potency, purity, molecular-weight distribution, and impurity detection. Heparin cannot be treated like a simple small-molecule active ingredient.

The 2008 heparin contamination crisis demonstrated that conventional potency testing alone may not detect all clinically important adulterants. [2] A supplier with advanced impurity surveillance and reliable documentation can obtain a commercial advantage even without broad patent coverage.

Sterile manufacturing

The product requires validated aseptic processing or terminal sterilization, depending on the formulation and container system. Key manufacturing risks include:

• Bioburden
• Endotoxin
• Particulates
• Fill-volume variation
• Container-closure defects
• Mix-up between heparin concentrations
• Labeling and barcode errors

A manufacturer that already operates sterile large-volume parenteral lines has a structural advantage.

What commercial opportunities exist for manufacturers?

The most attractive opportunities are in supply reliability and hospital workflow.

Opportunity	Commercial rationale	Main development issue
Ready-to-use premix bags	Reduces pharmacy preparation	Demonstrate stability and administration compatibility
Dual concentration portfolio	Fits more hospital protocols	Medication-error control
Non-PVC container	Differentiates packaging and may address institutional preferences	Cost and extractables package
Smaller-volume bag	Supports selected infusion workflows	Dose-volume and pump compatibility
Regional supply redundancy	Addresses shortage and procurement risk	Qualified heparin source
Private-label supply	Uses established hospital purchasing channels	Manufacturing scale and quality agreements
Contract manufacturing	Supports hospitals and distributors	Capacity and regulatory control
Integrated barcode packaging	Reduces selection errors	Serialization and systems compatibility
Extended shelf life	Lowers waste and emergency-ordering risk	Long-term stability program

A new entrant is more likely to win through dependable fill-finish capacity, competitive hospital contracting, and shortage response than through a novel excipient.

How does heparin sodium in sodium chloride compare with competing anticoagulant products?

Product	Primary advantage	Primary limitation	Excipient opportunity
Unfractionated heparin in saline	Rapid titration and reversibility	Variable response and monitoring burden	Premix concentration, packaging and stability
Enoxaparin injection	Fixed subcutaneous dosing	Less convenient for rapid titration	Prefilled syringe and device usability
Bivalirudin injection	Alternative in selected procedural settings	Higher cost and reconstitution requirements	Ready-to-use liquid presentation
Argatroban injection	Use in selected heparin-induced thrombocytopenia cases	Cost and monitoring requirements	Premix and container optimization
Direct oral anticoagulants	Oral administration	Limited use in acute procedural infusion settings	Tablet formulation rather than saline premix

Heparin remains commercially relevant because it is titratable, familiar, rapidly acting, and reversible with protamine. That clinical profile supports ongoing demand for hospital premix products even when newer anticoagulants compete in other settings.

What is the likely generic launch scenario?

A generic launch would most likely occur through one of four routes:

1. A conventional ANDA for a directly comparable heparin sodium injection presentation
2. A line extension with a different bag size or concentration
3. A private-label product manufactured by an established sterile injectable supplier
4. A differentiated product using a new container, device interface, or stability profile

The fastest commercial path is usually a formulation and packaging configuration that remains close to the reference product. A materially different excipient system may create additional clinical, analytical, and regulatory work without providing meaningful pricing power.

Generic competition can reduce reimbursement and contract pricing quickly because the active ingredient and vehicle are mature. Market share is therefore likely to depend on:

• Backorder performance
• Supply continuity
• National group purchasing organization contracts
• Hospital formulary status
• Product concentration coverage
• Case-pack economics
• Recall history
• Quality-system reputation

What is the Orange Book and exclusivity position?

For a mature heparin sodium premix, regulatory exclusivity is generally limited compared with newly approved small-molecule products. New chemical entity exclusivity is not available for heparin sodium. A manufacturer would need to establish a qualifying new product, indication, or regulatory feature to obtain meaningful exclusivity.

The relevant review items are:

• Current Orange Book listing for the selected reference product
• Any listed patents by strength and dosage form
• FDA approval date
• Any remaining non-patent exclusivity
• Approved labeling and presentation-specific differences
• FDA shortage status and product availability

The Orange Book should be checked at the time of filing because listings, patents, and product status can change. [1]

What patent and licensing strategy is commercially realistic?

A realistic IP strategy would focus on narrow, technically supported claims:

• A defined container system that reduces heparin loss
• A validated formulation that maintains potency in a specific polymer system
• A manufacturing process that removes defined impurities
• A stable premix with a specified concentration range and shelf life
• A closed-system administration package
• A device-assisted dosing or infusion configuration

Licensing opportunities are more likely to involve:

• Heparin raw-material supply
• Sterile fill-finish capacity
• Container technology
• Hospital distribution
• Barcode and medication-safety systems
• Regional rights to a premix portfolio

Licensing a basic sodium chloride formulation alone is unlikely to create substantial value unless the agreement includes manufacturing capacity, supply rights, regulatory approvals, or proprietary packaging technology.

Key Takeaways

• Heparin sodium in sodium chloride is a mature, FDA-approved sterile injectable product.
• The basic formulation has limited patent strength and little prospect of broad composition-of-matter protection.
• The commercial opportunity is concentrated in ready-to-use presentation, concentration selection, container performance, supply reliability, and hospital procurement.
• Sodium chloride and water for injection are the core excipients; preservative-free design is generally the most practical approach.
• The most important technical risks are heparin source variability, impurity control, adsorption, container compatibility, sterility, endotoxin, and labeling errors.
• The product is not normally a biosimilar; generic development is generally pursued through a drug approval pathway.
• A differentiated container, manufacturing process, or integrated delivery system offers more defensible IP than a basic heparin-in-saline composition.
• Raw-material qualification and sterile manufacturing capacity are likely to create stronger barriers than patents.

FAQs

Can heparin sodium in sodium chloride be formulated with dextrose instead of saline?

Yes, alternative diluents may be technically possible, but the product would require its own compatibility, stability, osmolality, labeling, and regulatory assessment. Sodium chloride remains the commercially familiar vehicle for standard hospital premixes.

Does a ready-to-use heparin bag require a new clinical trial?

Not necessarily. The regulatory requirement depends on the proposed formulation, reference product, route, strength, container, and application pathway. A formulation closely matching an approved reference product may avoid a large efficacy trial, but it still requires a robust pharmaceutical equivalence and stability package.

Is heparin sodium in saline subject to cold-chain distribution?

Commercial requirements depend on the approved label and container system. A product that supports controlled room-temperature storage has a logistical advantage over one requiring refrigerated distribution, but the claim must be supported by validated stability data.

Can a manufacturer patent a new heparin concentration?

A concentration alone is usually a weak basis for patent protection unless it is tied to a new technical effect, delivery system, stability result, dosing method, or clinically meaningful use that satisfies patentability requirements.

What is the highest-value formulation improvement?

For most manufacturers, the highest-value improvement is a validated ready-to-use presentation that combines reliable heparin potency, low adsorption, long shelf life, clear concentration labeling, and dependable supply. The value comes from hospital workflow and procurement performance rather than excipient novelty.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2008). Heparin sodium injection recall and contamination information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/heparin-sodium-injection

3. U.S. Food and Drug Administration. (2020). Heparin sodium injection: Product-specific guidance for industry. https://www.fda.gov/drugs/drug-guidances

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Heparin sodium and sodium chloride injection monographs. Rockville, MD: U.S. Pharmacopeial Convention.

5. DailyMed. (2024). Heparin sodium in sodium chloride injection prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/